Skip to main content

Table 4 Fatty acid distribution of cellular lipids treated with different milk lipids at 24 h

From: Influence of in vitro supplementation with lipids from conventional and Alpine milk on fatty acid distribution and cell growth of HT-29 cells

  Control   MLcon MLalp
  0.25% EtOH   100 μM   200 μM   100 μM   200 μM  
FAME [%] Mean   SD   Mean   SD   Mean   SD   Mean   SD   Mean   SD  
C14:0 1.67 ± 0.32 d 6.26 ± 0.34 b 8.33 ± 0.61 a 5.36 ± 0.28 c 6.86 ± 0.46 b
C14:1 c 9 0.17 ± 0.06 c 0.55 ± 0.09 ab 0.67 ± 0.15 a 0.46 ± 0.06 b 0.54 ± 0.07 ab
C15:0 0.21 ± 0.01 c 0.81 ± 0.06 b 1.04 ± 0.04 a 0.85 ± 0.04 b 1.12 ± 0.05 a
C16:0 20.48 ± 0.71 d 30.34 ± 1.27 b 34.36 ± 1.34 a 24.56 ± 0.65 c 25.57 ± 0.29 c
C16:1 c 9 15.44 ± 0.97 a 11.82 ± 1.23 b 9.45 ± 1.09 c 9.31 ± 0.95 c 6.96 ± 0.73 d
C16:2 t 7,c 9 -   -   -   0.07 ± 0.01 b 0.08 ± 0.00 a
C17:0 0.32 ± 0.01 a 0.54 ± 0.04 c 0.59 ± 0.03 b 0.59 ± 0.04 b 0.68 ± 0.03 d
C18:0 10.97 ± 0.89 a 9.39 ± 0.32 b 8.77 ± 0.34 b 9.03 ± 0.21 b 8.71 ± 0.25 b
C18:1 c 9 36.95 ± 0.87 a 28.67 ± 0.64 d 26.09 ± 0.27 e 31.63 ± 0.99 b 30.27 ± 0.34 c
C18:1 c 11 3.04 ± 0.20 a 1.77 ± 0.15 b 1.33 ± 0.09 a 1.84 ± 0.05 b 1.39 ± 0.11 a
C18:1 c 12-15 -   0.29 ± 0.15 a 0.38 ± 0.07 a 0.41 ± 0.13 a 0.43 ± 0.10 a
C18:1 t 4-8 -   0.02 ± 0.01 bc 0.04 ± 0.02 bc 0.07 ± 0.04 ab 0.10 ± 0.05 a
C18:1 t 9 -   0.09 ± 0.02 c 0.12 ± 0.03 bc 0.15 ± 0.04 ab 0.20 ± 0.06 a
C18:1 t 10 -   0.10 ± 0.02 b 0.14 ± 0.03 b 0.14 ± 0.04 b 0.20 ± 0.03 a
C18:1 t 11 (VA) -   0.18 ± 0.04 c 0.28 ± 0.05 c 1.86 ± 0.25 b 2.73 ± 0.27 a
C18:1 t 12-16 -   0.35 ± 0.09 c 0.58 ± 0.08 b 0.56 ± 0.13 b 0.81 ± 0.18 a
C18:2 n-6 2.13 ± 0.18 a 1.91 ± 0.12 bc 1.73 ± 0.07 c 2.13 ± 0.09 a 2.00 ± 0.04 ab
C18:2 n-6 (t,t) -   0.13 ± 0.05 d 0.22 ± 0.03 c 0.28 ± 0.05 b 0.42 ± 0.03 a
C18:2 c 9,t 11 0.07 ± 0.02 d 0.35 ± 0.02 c 0.40 ± 0.02 c 2.90 ± 0.27 b 3.57 ± 0.18 a
C18:2 t 11,c 13 -   -   -   0.15 ± 0.02 b 0.21 ± 0.02 a
C18:2 t 9,t 11 -   0.04 ± 0.01 c 0.04 ± 0.01 c 0.19 ± 0.02 b 0.21 ± 0.02 a
C18:3 n-3 0.20 ± 0.03 d 0.35 ± 0.03 c 0.39 ± 0.03 c 1.03 ± 0.09 b 1.26 ± 0.06 a
C20:0 0.35 ± 0.02 a 0.30 ± 0.02 b 0.28 ± 0.01 bc 0.30 ± 0.01 b 0.27 ± 0.01 c
C20:1 c 9 0.41 ± 0.05 a 0.19 ± 0.04 cd 0.15 ± 0.00 d 0.26 ± 0.02 b 0.21 ± 0.01 bc
C20:3 n-6 0.97 ± 0.12 a 0.55 ± 0.01 b 0.38 ± 0.01 c 0.53 ± 0.02 b 0.36 ± 0.02 c
C20:4 n-6 1.82 ± 0.19 a 1.00 ± 0.02 b 0.66 ± 0.03 c 0.95 ± 0.04 b 0.63 ± 0.04 c
C20:5 n-3 0.53 ± 0.05 a 0.29 ± 0.02 bc 0.21 ± 0.01 d 0.33 ± 0.02 b 0.25 ± 0.01 cd
C22:5 n-3 1.04 ± 0.15 a 0.59 ± 0.03 b 0.42 ± 0.01 c 0.62 ± 0.05 b 0.43 ± 0.03 c
C22:6 n-3 1.31 ± 0.12 a 0.70 ± 0.03 b 0.45 ± 0.03 c 0.70 ± 0.05 b 0.43 ± 0.04 c
∑ SFA 35.66 ± 1.27 e 49.81 ± 1.52 b 55.66 ± 1.15 a 43.14 ± 1.00 d 45.98 ± 0.53 c
∑ MUFA 56.10 ± 1.15 a 44.15 ± 1.60 c 39.35 ± 1.17 d 46.84 ± 0.86 b 43.99 ± 0.63 c
∑ PUFA incl. CLA 8.24 ± 0.78 b 6.04 ± 0.20 c 4.99 ± 0.06 d 10.05 ± 0.57 a 10.03 ± 0.17 a
∑ PUFA n-3 3.20 ± 0.34 a 2.01 ± 0.07 d 1.51 ± 0.04 e 2.78 ± 0.17 b 2.47 ± 0.04 c
∑ PUFA n-6 4.97 ± 0.47 a 3.51 ± 0.13 b 2.82 ± 0.06 c 3.67 ± 0.13 b 3.07 ± 0.04 c
PUFA/SFA 0.23 ± 0.03 a 0.12 ± 0.00 b 0.09 ± 0.00 c 0.23 ± 0.02 a 0.22 ± 0.00 a
n-6/n-3 1.56 ± 0.07 c 1.75 ± 0.07 b 1.87 ± 0.07 a 1.32 ± 0.03 d 1.25 ± 0.01 d
∑ SFA + t FA 35.66 ± 1.27 d 50.75 ± 1.62 b 57.13 ± 1.33 a 46.28 ± 1.17 c 50.56 ± 1.04 b
∑ C18:1 (t) -   0.74 ± 0.16 c 1.16 ± 0.18 c 2.78 ± 0.45 b 4.05 ± 0.55 a
C18:1 t 9/t 11 -   0.51 ± 0.07 a 0.42 ± 0.07 b 0.08 ± 0.02 c 0.07 ± 0.02 c
∑ CLA 0.07 ± 0.02 d 0.39 ± 0.02 c 0.44 ± 0.02 c 3.26 ± 0.33 b 3.99 ± 0.17 a
VA + C18:2 c 9,t 11 0.07 ± 0.02 d 0.52 ± 0.05 cd 0.68 ± 0.06 c 4.75 ± 0.52 b 6.30 ± 0.40 a
∑ BCFA 0.37 ± 0.10 d 1.36 ± 0.13 c 1.68 ± 0.10 b 1.72 ± 0.17 b 2.16 ± 0.11 a
  1. FA distribution of HT-29 cells after incubation with milk lipids (ML conventional and ML Alpine) given as FFA-mixtures in ethanol. Means (n = 6) of FAME [%] significantly differ without the same letter (a, b, c, d), two-way ANOVA Tukey post hoc test P < 0.05.